Evidence map›Paper›PMID 40528299›Full record

ReviewAlzheimer's & dementia : the journal of the Alzheimer's Association2025

A hypothesis explaining Alzheimer's disease, Parkinson's disease, and dementia with Lewy bodies overlap.

Victor Z Lau, Ifeoluwa O Awogbindin, Dan Frenkel, Shawn N Whitehead, Marie-Ève Tremblay

Abstract readReview
In one paragraph

Review in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. A hypothesis explaining Alzheimer's disease, Parkinson's disease, and dementia with Lewy bodies overlap.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Victor Z LauDivision of Medical Sciences, University of Victoria, Victoria, British Columbia, Canada.ORCID 0000-0003-1147-2073
Ifeoluwa O AwogbindinDivision of Medical Sciences, University of Victoria, Victoria, British Columbia, Canada.ORCID 0000-0002-6786-3658
Dan FrenkelDepartment of Neurobiology, The School of Neurobiology, Biochemistry, and Biophysics, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv-Yafo, Israel.ORCID 0000-0002-7494-6857
Shawn N WhiteheadVulnerable Brain Laboratory, Department of Anatomy and Cell Biology, The Schulich School of Medicine & Dentistry, The University of Western Ontario, London, Ontario, Canada.ORCID 0000-0003-4728-8067
Marie-Ève TremblayDivision of Medical Sciences, University of Victoria, Victoria, British Columbia, Canada.ORCID 0000-0003-2863-9626

Funding

College MemberFaculty of Graduate Studies, University of Victoria & Canadian Institute of Health ResearchHealth Research BCJoint Canada-Israel Health Research ProgramParkinson Society BCRoyal Society of Canada
6 · The paper itself

Abstract

Lewy body-involving diseases (LBD) are commonly associated with Parkinson's disease (PD) featuring voluntary movement inhibition, due to dopaminergic neuron dysfunction in the substantia nigra. PD is clinically tracked through Lewy bodies (LB), composed of insoluble α-synuclein aggregates sequestered with organelles, particularly inside neurons. However, α-synuclein pathology also appears in incidental LBD, Parkinson's disease dementia, and dementia with LB (DLB). Incomplete explanations address how these clinical pathologies interrelate, LBD etiology variability, and frequently overlapping α-synuclein and Alzheimer's disease (AD) pathologies. We hypothesize that (1) chronic environmental insult exposure and (2) senescence(-like) neuron accumulation contribute toward initiating and sustaining LBD; individual cell vulnerability determines either cell reactivity, death, or senescence in response to environmental insults. We predicate that parkinsonian and other neurodegenerative symptoms over LBD progression involve (3) co-occurring AD pathologies, wherein dementia symptomology develops when synergistic glial senescence, tau hyperphosphorylation, and possible α-synuclein aggregation reach into regions involved in AD progression. HIGHLIGHTS: Senescence burden is predicted to explain α-synucleinopathy progression. Senescence and cell death are hypothesized to occur in α-synucleinopathies. Sub-apoptotic stress is proposed to induce senescence in α-synucleinopathies. Neuronal senescence likely first spreads α-synucleinopathies to new regions. Glial senescence likely underlies Parkinson's disease and Alzheimer's disease overlap.

Indexed as

Alzheimer DiseaseLewy Body DiseaseParkinson Diseasealpha-SynucleinDisease ProgressionHumansLewy Bodiesalpha-Synucleinalpha‐synucleinAlzheimer's diseaseastrocytescellular senescencedementia with Lewy bodiesmicroglianeuronsParkinson's diseaseParkinson's disease dementia

Identifiers

PMID40528299
PMCPMC12173844

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.